Recent News

• 09.11.2025 - MAIA Biotechnology Highlights Positive Efficacy Data from THIO-101 Phase 2 Clinical Trial in Non-Small Cell Lung Cancer
• 09.05.2025 - MAIA Biotechnology Abstract Selected for Poster Presentation at 2025 IASLC World Conference on Lung Cancer
• 08.27.2025 - MAIA Biotechnology Announces Publication of Interim Clinical Data on Telomere Targeting Anticancer Agent in Peer-Reviewed Journal Cells
• 08.13.2025 - MAIA Biotechnology Granted European Patent for Next Generation Telomere-Targeting Agents for Cancer Therapy
• 07.28.2025 - MAIA Biotechnology Receives FDA’s Fast Track Designation for Ateganosine as a Treatment for Non-Small Cell Lung Cancer
• 07.17.2025 - MAIA Biotechnology Announces Peer-Reviewed Journal Publication of Data Validating Second Generation Ateganosine Prodrugs for Anticancer Therapy
• 07.09.2025 - MAIA Biotechnology Announces First Patient Dosed in Expansion of Phase 2 Trial for Ateganosine in Advanced Non-Small Cell Lung Cancer

Recent Filings

• 09.08.2025 - EX-99.1 EX-99.1
• 09.08.2025 - 8-K Current report
• 08.13.2025 - 8-K Current report
• 08.13.2025 - EX-99.1 EX-99.1
• 08.11.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 07.28.2025 - EX-99.1 EX-99.1
• 07.28.2025 - 8-K Current report
• 07.17.2025 - EX-99.1 EX-99.1
• 07.17.2025 - 8-K Current report
• 07.09.2025 - EX-99.1 EX-99.1